In conclusion, OI could improve the viability of HaCaT and D66H cells via regulating the KEAP1‐NRF2‐GCLC/HO‐1 pathway, which provided a wide spectrum of potential targets for effective therapeutic treatments of Vohwinkel syndrome in the clinic. Here, HMOX1 is linked to keratoderma hereditarium mutilans.